UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors.

CRS-207 caused tumor shrinkage in 85% of patients and the overall disease control rate was 94%.

Patients were given two bacterial of Listeria monocytogenes infusions two weeks apart, followed by 6 rounds of chemotherapy, and then two additional vaccinations at the end.

“CRS-207 is an exciting agent for patients with mesothelioma. Our preliminary results are encouraging, suggesting superior clinical activity when added to standard chemotherapy. This supports assessing the impact of CRS-207 in a randomised trial, which is currently in the planning stages and should be underway within this calendar year,” said Dr. Thierry M. Jahan, a clinical professor in the University of California San Francisco’s Department of Medicine and lead study investigator.

Article sources:

Powers, V. (2016, April 15). Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in Mesothelioma. Retrieved from http://www.onclive.com/conference-coverage/ELCC-2016/novel-vaccine-added-to-chemotherapy-improves-patient-outcomes-in-mesothelioma

Panjwani, L. (2016, May 16). Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma. Retrieved from http://www.onclive.com/web-exclusives/expert-discusses-promise-of-crs-207-vaccine-in-mesothelioma